UKIPO appoints permanent chief executive
Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.
Third Circuit backs pharma firm in antitrust clash
Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.
Amgen seals $28m deal for biotech
Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.
IPH firm unveils new MD in Sydney
Firm promotes life sciences lead | New managing partner will play a role in international IP services group.
Pfizer and partner hit back in COVID-19 vaccine dispute
Big pharma firm accused of copying technology when developing vaccine | Dispute will also play out in Germany | BioNTech | Moderna.
US supports delay to COVID waiver extension
Extension is “pathetic” says vaccine charity coalition | US Trade Representative says extra time will “help the world make a more informed decision” about the controversial patent waiver.
Brown Rudnick boosts practice with London hire
New addition comes from Fieldfisher | Practice will extend across the US, UK and Continental Europe | renewables and cleantech.
Gilead prevails in US government dispute
Agency found to have breached deal regarding research | Pharma firm accused of piggybacking on public research| Centers for Disease Control and Prevention.
Voluntary licensing opens up HIV treatment to 100 countries
Medicines Patent Pool deals have given 20 million people access to HIV treatment | Full list of sub-licensees.
MSD accuses university of patent contract breach
Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.
